Ibrutinib companion diagnostic - Abbott/Janssen/Pharmacyclics

Drug Profile

Ibrutinib companion diagnostic - Abbott/Janssen/Pharmacyclics

Latest Information Update: 28 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Biotech; Pharmacyclics
  • Developer Abbott Laboratories; Janssen Biotech; Pharmacyclics
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Chronic lymphocytic leukaemia

Most Recent Events

  • 26 May 2015 Pharmacyclics has been acquired by AbbVie
  • 21 Feb 2013 Clinical trials in Chronic lymphocytic leukaemia (diagnosis) in USA (ex vivo)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top